Several experts that we spoke with for ASCO 2024 share their thoughts on why the American Society of Clinical Oncology annual meeting is so important to the field of oncology.
Researchers Study Gentler Cancer Treatments voanews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from voanews.com Daily Mail and Mail on Sunday newspapers.
Scaling back treatment for three kinds of cancer can make life easier for patients without compromising outcomes, doctors reported at the world’s largest cancer conference. It’s part of a long-term trend toward studying whether doing less — less surgery, less chemotherapy or less radiation — can help patients live longer…
Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months. This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio s genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with newly diagnosed glioblastoma.